Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PCL
MCID: PLS016
MIFTS: 53

Plasma Cell Leukemia (PCL)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasma Cell Leukemia

About this section

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 12 20 58 54 15 17
Leukemia, Plasma Cell 20 44 70
Plasma Cell Leukaemia 12 32
Plasmacytic Leukaemia 12
Plasmacytic Leukemia 12
Pcl 58

Characteristics:

Orphanet epidemiological data:

58
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9513
ICD9CM 34 203.1
MeSH 44 D007952
NCIt 50 C3180
SNOMED-CT 67 269630009
ICD10 32 C90.1
ICD10 via Orphanet 33 C90.1
UMLS via Orphanet 71 C0023484
Orphanet 58 ORPHA454714
UMLS 70 C0023484
Sources

Summaries for Plasma Cell Leukemia

About this section
GARD : 20 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. For detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient/page4

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to leukemia and plasma cell neoplasm. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Doxorubicin and Thalidomide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and spleen, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A plasma cell neoplasm that is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.

Wikipedia : 73 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Sources

Related Diseases for Plasma Cell Leukemia

About this section

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 leukemia 31.1 NRAS MYC KRAS CDKN2A CCND1 BCL10
2 plasma cell neoplasm 30.8 SDC1 NRAS KRAS IL6 FGFR3
3 peripheral t-cell lymphoma 30.7 NCAM1 FGFR3 CD38 CCND1
4 plasmacytoma 30.6 NCAM1 MYC IRF4 IL6 CDKN2A CD38
5 macroglobulinemia 30.4 SDC1 IL6 CD40
6 exanthem 30.3 KRAS IL6 IFNA1
7 prolymphocytic leukemia 30.2 MYC CD38 CCND1
8 extramedullary plasmacytoma 30.1 SDC1 IRF4 IL6 CD38 CCND1
9 adenocarcinoma 30.1 MYC KRAS FGFR3 CDKN2A CCND1
10 myeloma, multiple 30.0 SDC1 NRAS NCAM1 MYC MAF KRAS
11 central nervous system lymphoma 30.0 MYC IL6 CDKN2A
12 thyroiditis 30.0 IL6 IFNA1 CD40
13 peripheral nervous system disease 29.9 NCAM1 MYC IL6 CDKN2A CD44 CCND1
14 cervical adenocarcinoma 29.9 MYC KRAS CDKN2A
15 lung cancer susceptibility 3 29.9 NRAS MYC KRAS FGFR3 CDKN2A CCND1
16 marginal zone b-cell lymphoma 29.9 SDC1 IRF4 CCND1 BCL10
17 adult t-cell leukemia 29.9 MYC IRF4 IFNA1 ICAM1 CDKN2A
18 thrombocytopenia 29.9 KRAS IRF4 IL6 IFNA1 ICAM1 CD44
19 t-cell lymphoblastic leukemia/lymphoma 29.9 MYC IRF4 ICAM1 CCND3 CCND1
20 leukemia, chronic myeloid 29.9 NRAS MYC KRAS IRF4 IFNA1
21 essential thrombocythemia 29.8 MYC KRAS IL6 IFNA1 CCND1
22 colorectal adenocarcinoma 29.8 MYC KRAS CDKN2A CD44 CCND1
23 cervical cancer 29.8 TP73 MYC FGFR3 CDKN2A CD44 CCND1
24 waldenstroem's macroglobulinemia 29.7 SDC1 IRF4 CD40 CD38 CCND1
25 lymphoma 29.6 MYC ITGB1 IRF4 IL6 CDKN2A CD44
26 squamous cell carcinoma 29.6 TP73 MYC FGFR3 CDKN2A CD44 CCND1
27 bone disease 29.6 SDC1 IL6 ICAM1 FGFR3
28 monoclonal gammopathy of uncertain significance 29.5 SDC1 NCAM1 MYC MAF IRF4 IL6
29 lymphoma, mucosa-associated lymphoid type 29.4 SDC1 MYC IRF4 CD40 CCND1 BCL10
30 skin carcinoma 29.3 NRAS NCAM1 MYC KRAS IL6 IFNA1
31 b-cell lymphoma 29.2 MYC IRF4 CDKN2A CD44 CD40 CCND3
32 mantle cell lymphoma 29.1 MYC IL6 CDKN2A CD44 CD40 CCND3
33 skin disease 29.1 NRAS ITGB1 IL6 IFNA1 ICAM1 FGFR3
34 sarcoma 29.0 NRAS MYC KRAS ITGB1 IL6 IFNA1
35 leukemia, acute myeloid 29.0 NRAS NCAM1 MYC KRAS IL6 IFNA1
36 melanoma 28.9 NRAS MYC KRAS ITGB1 IFNA1 ICAM1
37 burkitt lymphoma 28.9 MYC IRF4 IL6 IFNA1 ICAM1 CDKN2A
38 disease of mental health 28.8 NCAM1 MYC MAF IL6 IFNA1 ICAM1
39 diffuse large b-cell lymphoma 28.6 SDC1 MYC IRF4 IL6 CDKN2A CD40
40 leukemia, chronic lymphocytic 28.6 SDC1 NRAS NCAM1 MYC KRAS IRF4
41 hepatocellular carcinoma 28.6 NRAS MYC KRAS ITGB1 IL6 IFNA1
42 neuroblastoma 28.6 TP73 NRAS NCAM1 MYC ITGB1 IL6
43 ovarian cancer 28.3 TP73 MYC KRAS ITGB1 IL6 CDKN2A
44 lymphoma, non-hodgkin, familial 28.3 SDC1 NRAS NCAM1 MYC IRF4 IL6
45 lung cancer 28.3 TP73 NRAS NCAM1 MYC KRAS ITGB1
46 prostate cancer 28.3 TP73 MYC KRAS ITGB1 IL6 FGFR3
47 colorectal cancer 27.7 TP73 NRAS NCAM1 MYC KRAS ITGB1
48 lymphatic malformation 1 11.2
49 hereditary lymphedema i 11.0
50 post-traumatic stress disorder 10.5

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia
Sources

Symptoms & Phenotypes for Plasma Cell Leukemia

About this section

GenomeRNAi Phenotypes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.98 KRAS
2 Decreased viability GR00055-A-2 9.98 KRAS
3 Decreased viability GR00055-A-3 9.98 KRAS
4 Decreased viability GR00106-A-0 9.98 KRAS
5 Decreased viability GR00221-A-1 9.98 CDKN2A FGFR3 KRAS MYC NRAS
6 Decreased viability GR00221-A-2 9.98 FGFR3 KRAS
7 Decreased viability GR00221-A-3 9.98 CDKN2A FGFR3 MYC NRAS
8 Decreased viability GR00221-A-4 9.98 CDKN2A
9 Decreased viability GR00249-S 9.98 FGFR3 MYC
10 Decreased viability GR00301-A 9.98 KRAS
11 Decreased viability GR00381-A-1 9.98 KRAS
12 Decreased viability GR00402-S-2 9.98 MYC
13 Decreased cell migration GR00055-A-1 9.55 FGFR3 ITGB1
14 Decreased cell migration GR00055-A-2 9.55 NCAM1
15 Decreased cell migration GR00055-A-3 9.55 NCAM1 SDC1
16 Reduced mammosphere formation GR00396-S 9.17 CCND1 CCND3 CD44 KRAS MYC NCAM1

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.5 BCL10 CCND1 CCND3 CD38 CD40 CD44
2 cellular MP:0005384 10.49 BCL10 CCND1 CD38 CD44 CDKN2A FGFR3
3 immune system MP:0005387 10.48 BCL10 CCND1 CCND3 CD38 CD40 CD44
4 homeostasis/metabolism MP:0005376 10.47 CCND1 CCND3 CD38 CD40 CD44 CDKN2A
5 behavior/neurological MP:0005386 10.45 CCND1 CCND3 CD44 CDKN2A FGFR3 IL6
6 endocrine/exocrine gland MP:0005379 10.44 BCL10 CCND1 CCND3 CD38 CD40 CD44
7 growth/size/body region MP:0005378 10.4 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
8 cardiovascular system MP:0005385 10.38 CCND1 CCND3 CD44 CDKN2A ICAM1 IL6
9 mortality/aging MP:0010768 10.36 BCL10 CCND1 CCND3 CD44 CDKN2A FGFR3
10 digestive/alimentary MP:0005381 10.32 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6
11 integument MP:0010771 10.29 CCND1 CD44 CDKN2A FGFR3 ICAM1 IL6
12 neoplasm MP:0002006 10.28 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
13 nervous system MP:0003631 10.25 BCL10 CCND1 CD40 CD44 CDKN2A FGFR3
14 craniofacial MP:0005382 10.19 CCND1 FGFR3 ITGB1 KRAS MAF MYC
15 liver/biliary system MP:0005370 10.13 CCND3 CD44 CDKN2A IL6 ITGB1 KRAS
16 limbs/digits/tail MP:0005371 10.04 CD44 FGFR3 ITGB1 KRAS MAF MYC
17 normal MP:0002873 10.02 CCND1 CCND3 CD40 CD44 FGFR3 ITGB1
18 reproductive system MP:0005389 9.96 CCND1 CD44 CDKN2A FGFR3 IL6 ITGB1
19 respiratory system MP:0005388 9.81 CCND1 CCND3 CD44 CDKN2A FGFR3 IL6
20 pigmentation MP:0001186 9.8 CD44 CDKN2A ITGB1 KRAS MYC NRAS
21 skeleton MP:0005390 9.7 CCND1 CD40 CD44 CDKN2A FGFR3 IL6
22 vision/eye MP:0005391 9.47 CCND1 CCND3 CD44 CDKN2A FGFR3 ICAM1
Sources

Drugs & Therapeutics for Plasma Cell Leukemia

About this section

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
2
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
3
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
4
Carmustine Approved, Investigational Phase 2 154-93-8 2578
5
Etoposide Approved Phase 2 33419-42-0 36462
6
Daratumumab Approved Phase 2 945721-28-8
7
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
8
Gemcitabine Approved Phase 2 95058-81-4 60750
9
Elotuzumab Approved Phase 2 915296-00-3
10
Allopurinol Approved Phase 2 315-30-0 2094
11
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
13
Acetaminophen Approved Phase 2 103-90-2 1983
14
Promethazine Approved, Investigational Phase 2 60-87-7 4927
15
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
16
tannic acid Approved Phase 2 1401-55-4
17
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
18
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
19
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
20
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
21
Sodium citrate Approved, Investigational Phase 2 68-04-2
22
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
23
Ixazomib Approved, Investigational Phase 2 1072833-77-2
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
26
Ichthammol Approved Phase 2 8029-68-3
27
Pomalidomide Approved Phase 2 19171-19-8
28
Mycophenolic acid Approved Phase 2 24280-93-1 446541
29
Busulfan Approved, Investigational Phase 2 55-98-1 2478
30
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
31
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
33
Molgramostim Investigational Phase 1, Phase 2 99283-10-0
34
Filanesib Investigational Phase 1, Phase 2 885060-09-3
35
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
36
Liposomal doxorubicin Phase 2 31703
37 Immunoglobulin A Phase 2
38 interferons Phase 2
39 Tubulin Modulators Phase 2
40 Etoposide phosphate Phase 2
41 Antimitotic Agents Phase 1, Phase 2
42 Keratolytic Agents Phase 2
43 Podophyllotoxin Phase 2 518-28-5
44 Antiviral Agents Phase 2
45 Antimetabolites Phase 2
46 Histone Deacetylase Inhibitors Phase 2
47 Antilymphocyte Serum Phase 2
48 Methylprednisolone Acetate Phase 2
49 Antioxidants Phase 2
50 Protective Agents Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies Unknown status NCT01435720 Phase 1, Phase 2
3 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70: Phase II Multicentre Study Completed NCT02858999 Phase 2 PAD-VCD
4 A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
5 An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial Completed NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
7 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
8 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
9 Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting NCT02506959 Phase 2 Busulfan;Gemcitabine Hydrochloride;Melphalan;Panobinostat
10 Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma Recruiting NCT01729091 Phase 2 Lenalidomide;Melphalan
11 MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia. Recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
12 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
13 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32] Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
14 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
15 Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia Active, not recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
16 Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft Active, not recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
17 Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
18 Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
19 Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
20 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma Completed NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
21 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
22 A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01372540 Phase 1 Carfilzomib;Filanesib
23 A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
24 Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma Active, not recruiting NCT01163357 Phase 1 bortezomib;fludarabine phosphate;tacrolimus;sirolimus
25 Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia Withdrawn NCT03591744 Phase 1 Bortezomib;Dexamethasone;Lenalidomide;Pegylated Liposomal Doxorubicin Hydrochloride
26 Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
27 Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data Recruiting NCT03389347
28 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
29 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases Recruiting NCT01962636 Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil
30 Phase II Open Lable Clinical Study Efficacy and Safety of the Holistic Treatment for Young Patients With High-Risk Multiple Myeloma Recruiting NCT04008888 Melphalan Given IV;Fludarabine Injection;PI and dexamethasone as maintenance therapy;PI+IMids+Dexamethasone as Consolidated Chemotherapy
31 Expanded Access to Venetoclax Available NCT03123029 Venetoclax

Search NIH Clinical Center for Plasma Cell Leukemia

Cochrane evidence based reviews: leukemia, plasma cell

Sources

Genetic Tests for Plasma Cell Leukemia

About this section
Sources

Anatomical Context for Plasma Cell Leukemia

About this section

MalaCards organs/tissues related to Plasma Cell Leukemia:

40
Bone Marrow, Myeloid, Spleen, T Cells, B Cells, Endothelial, Lymph Node
Sources

Publications for Plasma Cell Leukemia

About this section

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 937)
# Title Authors PMID Year
1
Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. 61 54
18231917 2008
2
Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. 61 54
12017294 2002
3
Analysis of p73 and p53 gene deletions in multiple myeloma. 61 54
10602435 1999
4
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. 61 54
9844928 1998
5
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. 54 61
9369432 1997
6
Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32). 54 61
9220667 1997
7
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. 54 61
7524765 1994
8
Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. 61 54
7686332 1993
9
The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia. 61 54
1516003 1992
10
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. 54 61
1540875 1992
11
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. 61 54
1715218 1991
12
In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. 61 54
2060582 1991
13
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. 61
33784005 2021
14
Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs. 61
33801014 2021
15
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. 61
33673918 2021
16
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 61
33782538 2021
17
Bortezomib-Based Regimens and Plasma Cell Leukemia 61
33463973 2021
18
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. 61
33563890 2021
19
A clinical perspective on plasma cell leukemia; current status and future directions. 61
33563906 2021
20
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia. 61
33278564 2021
21
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. 61
33392702 2021
22
Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report. 61
33644182 2021
23
Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation. 61
33796234 2021
24
90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. 61
32710011 2021
25
Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents. 61
33716516 2021
26
Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy. 61
33483877 2021
27
Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. 61
33563579 2021
28
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. 61
32313109 2020
29
[Prognosis and Genetic Characteristics of Patients with Plasma Cell Leukemia]. 61
33283702 2020
30
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. 61
32961371 2020
31
[Prevalence investigation of plasma cell leukemia in China: a calculation based on national urban medical insurance in 2016]. 61
33445844 2020
32
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. 61
32936982 2020
33
Primary plasma cell leukemia mimicking a Pancoast tumor. 61
32833248 2020
34
A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab. 61
32318778 2020
35
Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas. 61
33180138 2020
36
CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry. 61
33002126 2020
37
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. 61
32624447 2020
38
Trend of depression and its association with sociodemographic and clinical factors among multiple myeloma hospitalizations: A Portuguese nationwide study from 2000 to 2015. 61
32658348 2020
39
[The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation]. 61
32987483 2020
40
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. 61
32401087 2020
41
Blastoid plasma cell leukemia mimicking acute leukemia. 61
32818251 2020
42
A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia. 61
31865846 2020
43
Plasma cell leukemia characterized by EDTA-dependent plasma cell agglutination: a case report. 61
32762230 2020
44
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. 61
32576578 2020
45
Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario. 61
32642366 2020
46
Secondary Plasma Cell Leukemia: A Case Report. 61
32577333 2020
47
Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. 61
32129510 2020
48
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. 61
32555163 2020
49
Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study 61
31769277 2020
50
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. 61
31969333 2020
Sources

Variations for Plasma Cell Leukemia

About this section
Sources

Expression for Plasma Cell Leukemia

About this section
Search GEO for disease gene expression data for Plasma Cell Leukemia.
Sources

Pathways for Plasma Cell Leukemia

About this section

Pathways related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 NRAS NCAM1 MYC KRAS ITGB1 IRF4
2
ERK Signaling 63
Show member pathways
 13.88 NRAS MYC KRAS ITGB1 IL6 FGFR3
3
GPCR Pathway 63
Show member pathways
 13.75 NRAS MYC KRAS ITGB1 IL6 FGFR3
4
TGF-Beta Pathway 63
Show member pathways
 13.59 NRAS MYC KRAS ITGB1 IL6 IFNA1
5
Akt Signaling 63
Show member pathways
 13.46 NRAS KRAS ITGB1 IL6 FGFR3 CD40
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.25 NRAS MYC KRAS IL6 IFNA1 ICAM1
7
PI3K-Akt signaling pathway 36
Show member pathways
 12.97 NRAS MYC KRAS ITGB1 IL6 IFNA1
8
Human cytomegalovirus infection 36
Show member pathways
 12.94 NRAS MYC KRAS IL6 IFNA1 ICAM1
9
Endometrial cancer 36
Show member pathways
 12.92 NRAS MYC KRAS ITGB1 CDKN2A CCND1
10
Allograft rejection 1 36
Show member pathways
 12.9 IL6 IFNA1 ICAM1 CD40 CCND1
11
Cytokine Signaling in Immune system 65
Show member pathways
 12.88 NRAS NCAM1 MYC KRAS ITGB1 IRF4
12
Gastric cancer 36
Show member pathways
 12.81 NRAS MYC KRAS CDKN2A CCND1
13
Degradation of the extracellular matrix 65
Show member pathways
 12.8 SDC1 NCAM1 ITGB1 ICAM1 CD44
14
Development HGF signaling pathway 23
Show member pathways
 12.77 TP73 SDC1 NRAS KRAS ITGB1
15
Apoptosis Modulation and Signaling 1
Show member pathways
 12.77 TP73 NRAS MYC KRAS IRF4 CDKN2A
16
Measles 36
Show member pathways
 12.77 TP73 MYC IL6 IFNA1 ICAM1 CD44
17
DREAM Repression and Dynorphin Expression 63
Show member pathways
 12.73 NRAS KRAS ITGB1 CCND3 CCND1
18
ErbB signaling pathway 36 1
Show member pathways
 12.67 NRAS MYC KRAS IL6 FGFR3 CCND1
19
T cell receptor signaling pathway 36
Show member pathways
 12.66 NRAS KRAS IRF4 IL6 BCL10
20
Immune response IL-23 signaling pathway 23
Show member pathways
 12.65 NRAS MYC KRAS ITGB1 IL6
21
NF-kappaB Signaling 4
12.61 NCAM1 IRF4 IFNA1 CD44 CD38 BCL10
22
Interferon gamma signaling 65
Show member pathways
 12.59 NCAM1 IRF4 IFNA1 ICAM1 CD44
23
Pathways in cancer 36
12.58 NRAS MYC KRAS ITGB1 IL6 IFNA1
24
Prolactin Signaling Pathway 1 36
Show member pathways
 12.54 NRAS MYC KRAS ITGB1 CCND1
25
MicroRNAs in cancer 36
12.53 NRAS MYC KRAS FGFR3 CDKN2A CD44
26
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.49 NRAS KRAS CD40 BCL10
27
Apoptosis Pathway 69
Show member pathways
 12.48 NRAS KRAS ITGB1 FGFR3
28
JAK-STAT signaling pathway 36
Show member pathways
 12.48 MYC IL6 IFNA1 CCND3 CCND1
29
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.47 NRAS MYC KRAS IRF4 BCL10
30
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.45 SDC1 KRAS ICAM1 CD44
31
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.45 NRAS KRAS ITGB1 IL6 FGFR3
32
DNA Damage Response 1
Show member pathways
 12.45 TP73 MYC CDKN2A CCND3 CCND1
33
Cell cycle 36 1
12.41 MYC CDKN2A CCND3 CCND1
34
Viral carcinogenesis 36
12.37 NRAS KRAS CDKN2A CCND3 CCND1
35
Transcriptional misregulation in cancer 36
12.33 MYC MAF IL6 CD40
36
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.31 MYC KRAS IRF4 IL6 IFNA1 FGFR3
37
Wnt Signaling Pathway and Pluripotency 1
Show member pathways
 12.29 MYC CD44 CCND3 CCND1
38
Cell surface interactions at the vascular wall 65
Show member pathways
 12.29 SDC1 NRAS KRAS ITGB1 CD44
39
Proteoglycans in cancer 36
12.29 SDC1 NRAS MYC KRAS ITGB1 CD44
40
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.28 MYC CDKN2A CCND3 CCND1
41
C-type lectin receptor signaling pathway 36
Show member pathways
 12.27 NRAS KRAS IL6 BCL10
42
Colorectal Cancer Metastasis 63
12.25 MYC KRAS IL6 CCND1
43
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.24 NRAS MYC KRAS ITGB1 FGFR3 CCND3
44
Hippo signaling pathway 36
12.22 TP73 MYC CCND3 CCND1
45
ECM-receptor interaction 36
Show member pathways
 12.22 SDC1 ITGB1 ICAM1 CD44
46
Cell adhesion molecules 36
12.19 SDC1 NCAM1 ITGB1 ICAM1 CD40
47
Signaling pathways regulating pluripotency of stem cells 36
12.17 NRAS MYC KRAS FGFR3
48
FoxO signaling pathway 36
Show member pathways
 12.15 NRAS KRAS IL6 CCND1
49
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.13 NCAM1 MYC ITGB1 IL6
50
Cellular senescence (KEGG) 36
12.11 NRAS MYC KRAS IL6 CDKN2A CCND3
Sources

GO Terms for Plasma Cell Leukemia

About this section

Cellular components related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 KRAS ITGB1 ICAM1 BCL10
2 focal adhesion GO:0005925 9.55 KRAS ITGB1 ICAM1 FGFR3 CD44
3 host cell nucleus GO:0042025 9.26 MYC MAF CCND3 CCND1
4 cell surface GO:0009986 9.23 SDC1 NCAM1 ITGB1 ICAM1 FGFR3 CD44

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 TP73 MYC MAF IRF4 IL6 CDKN2A
2 positive regulation of gene expression GO:0010628 9.98 MYC MAF KRAS IL6 CDKN2A
3 positive regulation of cell proliferation GO:0008284 9.91 MYC KRAS IL6 FGFR3 CD38 CCND1
4 positive regulation of apoptotic process GO:0043065 9.88 TP73 ITGB1 IL6 CDKN2A BCL10
5 positive regulation of transcription, DNA-templated GO:0045893 9.87 TP73 MYC IRF4 IL6 CDKN2A CD38
6 positive regulation of protein phosphorylation GO:0001934 9.84 KRAS CD40 CCND3 CCND1
7 leukocyte migration GO:0050900 9.83 SDC1 ITGB1 ICAM1 CD44
8 response to drug GO:0042493 9.8 TP73 MYC ICAM1 CD38 CCND1
9 MAPK cascade GO:0000165 9.77 NRAS NCAM1 MYC KRAS FGFR3
10 cellular response to lipopolysaccharide GO:0071222 9.76 IL6 ICAM1 CD40 BCL10
11 positive regulation of kinase activity GO:0033674 9.75 FGFR3 CD44 BCL10
12 Ras protein signal transduction GO:0007265 9.74 NRAS KRAS CDKN2A
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IL6 FGFR3 CD40
14 interferon-gamma-mediated signaling pathway GO:0060333 9.56 NCAM1 IRF4 ICAM1 CD44
15 CD40 signaling pathway GO:0023035 9.55 ITGB1 CD40
16 T-helper 17 cell lineage commitment GO:0072540 9.49 IRF4 IL6
17 response to glucocorticoid GO:0051384 9.46 SDC1 KRAS IL6 CCND1
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.35 KRAS IL6 ICAM1 CD40 BCL10
19 cytokine-mediated signaling pathway GO:0019221 9.28 SDC1 MYC KRAS ITGB1 IRF4 IL6

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 TP73 SDC1 NRAS NCAM1 MYC MAF
2 protein kinase binding GO:0019901 9.65 TP73 CDKN2A CCND3 CCND1 BCL10
3 virus receptor activity GO:0001618 9.5 NCAM1 ITGB1 ICAM1
4 transcription factor binding GO:0008134 9.43 TP73 MYC IRF4 CDKN2A CCND1 BCL10
5 protein-containing complex binding GO:0044877 9.17 NRAS MYC KRAS ITGB1 ICAM1 CCND1
6 MDM2/MDM4 family protein binding GO:0097371 9.16 TP73 CDKN2A
Sources

Sources for Plasma Cell Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....